Odyssean LLC Purchases Shares of 26,232 Twist Bioscience Corporation $TWST

Odyssean LLC acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 26,232 shares of the company’s stock, valued at approximately $2,699,000.

A number of other institutional investors and hedge funds have also bought and sold shares of TWST. Man Group plc acquired a new stake in Twist Bioscience during the second quarter worth approximately $5,997,000. Jupiter Topco LLC acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $5,200,000. Osterweis Capital Management Inc. acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $11,467,000. Legal & General Group Plc bought a new position in shares of Twist Bioscience during the second quarter worth approximately $12,549,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $8,215,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TWST. Robert W. Baird boosted their price target on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Canaccord Genuity Group lifted their target price on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Piper Sandler boosted their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a research report on Thursday, July 16th. Finally, Barclays raised their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

Twist Bioscience Stock Up 7.5%

Shares of NASDAQ TWST opened at $151.42 on Wednesday. The stock has a market capitalization of $9.50 billion, a P/E ratio of -68.21 and a beta of 2.14. The stock’s fifty day moving average is $103.22 and its 200 day moving average is $71.89. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $154.96. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period in the prior year, the business earned $0.33 earnings per share. Twist Bioscience’s quarterly revenue was up 23.2% compared to the same quarter last year. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Emily M. Leproust sold 113,318 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the completion of the transaction, the chief executive officer owned 818,938 shares of the company’s stock, valued at approximately $102,498,280.08. The trade was a 12.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. This trade represents a 0.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 151,529 shares of company stock valued at $17,708,772 in the last three months. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.